Internal Med Medical News about Dyslipidemias Drug Therapy, Combination

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

5. Rapid correction of low vitamin D status in nursing home residents

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Systematic Review: Comparative Effectiveness and Harms of Combination Therapy and Monotherapy for Dyslipidemia
Annals of Internal Medicine, 11/03/09

Sharma M et al. – This review of 102 studies found 2 trials that suggested lower target lipid levels were more often achieved with statin–ezetimibe combination therapy than with high–dose statin monotherapy. No firm trial evidence showed that combining a statin with another agent (bile–acid sequestrant, fibrate, ezetimibe, niacin, or omega–3 fatty acids) improved clinical outcomes (myocardial infarction, stroke, or mortality) more often than high–dose statin monotherapy.

<< Previous
Systematic Review: Sodium Bicarbonate Treatment Regimens for the...

Next >>
Pulmonary embolism in pregnancy

Monotherapy versus combination therapy for the treatment of chronic hepatitis B
Expert Opinion on Investigational Drugs, 10/26/09 Relevance Score: 82%

Disparate Response to Metoclopramide Therapy for Gastric Feeding Intolerance in Trauma Patients With and Without Traumatic Brain Injury
Journal of Parenteral and Enteral Nutrition, 11/10/09 Relevance Score: 81%

FDA approves Twynsta a new single pill combination that delivers powerful and consistent blood pressure reductions throughout 24 hours
Boehringer Ingelheim, 10/20/09 Relevance Score: 81%

Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence
Current Medical Research and Opinion, 10/05/09 Relevance Score: 81%

Gilead Sciences Announces Plans for Phase IV Clinical Trial Evaluating First-Line Combination Therapy Versus Monotherapy in Pulmonary Arterial Hypertension
Gilead, 11/03/09 Relevance Score: 80%